House dust mite immunotherapy: A real-world, prescription data-based analysis

IF 4.6 2区医学 Q2 ALLERGY

Clinical and Translational Allergy Pub Date : 2024-07-11 DOI:10.1002/clt2.12382

R. Mösges, H. Richter, A. Sager, J. Weber, T. Müller

{"title":"House dust mite immunotherapy: A real-world, prescription data-based analysis","authors":"R. Mösges, H. Richter, A. Sager, J. Weber, T. Müller","doi":"10.1002/clt2.12382","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>House dust mite (HDM) sensitisation can contribute to the development of allergic rhinoconjunctivitis (AR) or allergic asthma (AA). As treatment, allergen immunotherapy (AIT) is a promising approach, since it aims building immunotolerance against allergens, therewith establishing long-term efficacy. The evaluation of AIT has been investigated in many randomised controlled trials, whereas few real-world evidence studies are available.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We used data from the longitudinal prescription data base IQVIA™ LRx. Data on initial AIT prescriptions against HDM from January 2009 to December 2013 was analysed regarding treatment (subcutaneous AIT with either depigmented polymerised allergen extract [dSCIT] or other allergens [oSCIT], or sublingual immunotherapy [SLIT]) and treatment duration. Treatment groups were compared with a control group of AR patients not receiving AIT. Data on symptomatic medication was collected until February 2017 and progression of AR and AA was compared.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Data of 7260 patients with AIT prescriptions and of 21,780 control patients was analysed. AIT was associated with a significant decrease of AR medication intake compared with control (dSCIT: −34.0%, <i>p</i> < 0.0001; oSCIT: −25.7%, <i>p</i> < 0.0001; SLIT: −37.7%, <i>p</i> = 0.0026). In asthmatics, SCIT was associated with a significant decrease of asthma medication compared with control (dSCIT: −45.2%, <i>p</i> < 0.0001; oSCIT: −32.9%, <i>p</i> < 0.0001). Further, a significantly reduced likelihood for onset of asthma medication was demonstrated in patients treated with SCIT compared with controls (dSCIT OR: 0.759, <i>p</i> = 0.0476; oSCIT OR: 0.815, <i>p</i> = 0.0339).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Real-world data analyses indicate that AIT, particularly given via a subcutaneous route, reduces the need of medication against AR and AA and might delay the onset of asthma medication in patients with AR.</p>\n </section>\n </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12382","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Allergy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/clt2.12382","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

House dust mite (HDM) sensitisation can contribute to the development of allergic rhinoconjunctivitis (AR) or allergic asthma (AA). As treatment, allergen immunotherapy (AIT) is a promising approach, since it aims building immunotolerance against allergens, therewith establishing long-term efficacy. The evaluation of AIT has been investigated in many randomised controlled trials, whereas few real-world evidence studies are available.

Methods

We used data from the longitudinal prescription data base IQVIA™ LRx. Data on initial AIT prescriptions against HDM from January 2009 to December 2013 was analysed regarding treatment (subcutaneous AIT with either depigmented polymerised allergen extract [dSCIT] or other allergens [oSCIT], or sublingual immunotherapy [SLIT]) and treatment duration. Treatment groups were compared with a control group of AR patients not receiving AIT. Data on symptomatic medication was collected until February 2017 and progression of AR and AA was compared.

Results

Data of 7260 patients with AIT prescriptions and of 21,780 control patients was analysed. AIT was associated with a significant decrease of AR medication intake compared with control (dSCIT: −34.0%, p < 0.0001; oSCIT: −25.7%, p < 0.0001; SLIT: −37.7%, p = 0.0026). In asthmatics, SCIT was associated with a significant decrease of asthma medication compared with control (dSCIT: −45.2%, p < 0.0001; oSCIT: −32.9%, p < 0.0001). Further, a significantly reduced likelihood for onset of asthma medication was demonstrated in patients treated with SCIT compared with controls (dSCIT OR: 0.759, p = 0.0476; oSCIT OR: 0.815, p = 0.0339).

Conclusion

Real-world data analyses indicate that AIT, particularly given via a subcutaneous route, reduces the need of medication against AR and AA and might delay the onset of asthma medication in patients with AR.

Abstract Image

查看原文本刊更多论文

屋尘螨免疫疗法：基于处方数据的真实世界分析。

背景：屋尘螨（HDM）致敏可导致过敏性鼻结膜炎（AR）或过敏性哮喘（AA）的发生。过敏原免疫疗法（AIT）是一种很有前景的治疗方法，因为它旨在建立对过敏原的免疫耐受，从而确立长期疗效。许多随机对照试验都对 AIT 的评估进行了调查，但实际证据研究却很少：我们使用了纵向处方数据库 IQVIA™ LRx 中的数据。我们分析了 2009 年 1 月至 2013 年 12 月期间针对人类乳头瘤病毒的首次 AIT 处方数据，包括治疗方法（皮下 AIT，使用去色素聚合过敏原提取物 [dSCIT] 或其他过敏原 [oSCIT]，或舌下免疫疗法 [SLIT]）和治疗持续时间。治疗组与未接受 AIT 的 AR 患者对照组进行比较。收集了截至2017年2月的症状用药数据，并对AR和AA的进展情况进行了比较：分析了7260名开具AIT处方的患者和21780名对照组患者的数据。与对照组相比，AIT 与 AR 药物摄入量的显著减少有关（dSCIT：-34.0%，p 结论：AIT 与 AR 药物摄入量的显著减少有关：真实世界的数据分析表明，AIT（尤其是通过皮下注射途径）可减少 AR 和 AA 的用药需求，并可推迟 AR 患者开始使用哮喘药物的时间。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Translational Allergy Immunology and Microbiology-Immunology

CiteScore

7.50

自引率

4.50%

发文量

117

审稿时长

12 weeks

期刊介绍： Clinical and Translational Allergy, one of several journals in the portfolio of the European Academy of Allergy and Clinical Immunology, provides a platform for the dissemination of allergy research and reviews, as well as EAACI position papers, task force reports and guidelines, amongst an international scientific audience. Clinical and Translational Allergy accepts clinical and translational research in the following areas and other related topics: asthma, rhinitis, rhinosinusitis, drug hypersensitivity, allergic conjunctivitis, allergic skin diseases, atopic eczema, urticaria, angioedema, venom hypersensitivity, anaphylaxis, food allergy, immunotherapy, immune modulators and biologics, animal models of allergic disease, immune mechanisms, or any other topic related to allergic disease.